Minerva Advisors’s ImmuCell ICCC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-11,958
Closed -$61.1K 66
2023
Q1
$61.1K Hold
11,958
0.04% 66
2022
Q4
$72.1K Hold
11,958
0.05% 64
2022
Q3
$89K Hold
11,958
0.07% 64
2022
Q2
$102K Hold
11,958
0.07% 64
2022
Q1
$113K Hold
11,958
0.07% 65
2021
Q4
$95K Hold
11,958
0.06% 71
2021
Q3
$107K Hold
11,958
0.06% 72
2021
Q2
$113K Hold
11,958
0.06% 70
2021
Q1
$113K Sell
11,958
-2,601
-18% -$24.4K 0.06% 71
2020
Q4
$87K Hold
14,559
0.05% 74
2020
Q3
$79K Hold
14,559
0.05% 72
2020
Q2
$69K Hold
14,559
0.05% 72
2020
Q1
$55K Hold
14,559
0.04% 76
2019
Q4
$75K Hold
14,559
0.04% 80
2019
Q3
$77K Hold
14,559
0.04% 80
2019
Q2
$95K Hold
14,559
0.05% 78
2019
Q1
$93K Hold
14,559
0.05% 79
2018
Q4
$100K Hold
14,559
0.06% 75
2018
Q3
$121K Hold
14,559
0.06% 73
2018
Q2
$98K Hold
14,559
0.05% 70
2018
Q1
$102K Hold
14,559
0.05% 70
2017
Q4
$119K Hold
14,559
0.06% 68
2017
Q3
$93K Hold
14,559
0.05% 70
2017
Q2
$103K Hold
14,559
0.06% 71
2017
Q1
$79K Hold
14,559
0.04% 71
2016
Q4
$85K Hold
14,559
0.05% 66
2016
Q3
$112K Hold
14,559
0.07% 68
2016
Q2
$101K Hold
14,559
0.07% 65
2016
Q1
$100K Hold
14,559
0.07% 66
2015
Q4
$108K Hold
14,559
0.07% 70
2015
Q3
$87K Buy
+14,559
New +$119K 0.06% 72

Other funds holding ICCC

Minerva Advisors's ICCC Position: Q2 2023 in Review

Minerva Advisors sold out of ImmuCell (ICCC) in Q2 2023, closing a stake of 11,958 shares — an estimated $61.1K sold.

Minerva Advisors first reported a position in ICCC in Q3 2015 and held it in 31 quarters. The position peaked at $121K in Q3 2018. 31 funds tracked by Wall St. Rank hold ICCC as of Q2 2023.

  • Minerva Advisors reported no remaining ImmuCell position as of Q2 2023 after selling out during the quarter.
  • Minerva Advisors sold 11,958 ImmuCell shares in Q2 2023, an estimated $61.1K.
  • Minerva Advisors first reported a position in ImmuCell in Q3 2015 and held it in 31 quarters.
  • Minerva Advisors's ImmuCell position peaked at $121K in Q3 2018.
  • 31 funds tracked by Wall St. Rank held ImmuCell as of Q2 2023.

Based on Minerva Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.